[go: up one dir, main page]

WO2001079551A1 - Haplotypes du gene nat1 - Google Patents

Haplotypes du gene nat1 Download PDF

Info

Publication number
WO2001079551A1
WO2001079551A1 PCT/US2001/011852 US0111852W WO0179551A1 WO 2001079551 A1 WO2001079551 A1 WO 2001079551A1 US 0111852 W US0111852 W US 0111852W WO 0179551 A1 WO0179551 A1 WO 0179551A1
Authority
WO
WIPO (PCT)
Prior art keywords
natl
gene
haplotype
individual
acetyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/011852
Other languages
English (en)
Inventor
Steven C. Bentivegna
Julie Y. Choi
Beena Koshy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cogenics Inc
Original Assignee
Genaissance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals Inc filed Critical Genaissance Pharmaceuticals Inc
Priority to AU2001255316A priority Critical patent/AU2001255316A1/en
Publication of WO2001079551A1 publication Critical patent/WO2001079551A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • This invention relates to variation in genes that encode pharmaceutically-important proteins.
  • this invention provides genetic variants of the human N-acetyltransferase l(arylamine N-acetyltransferase) (NATl) gene and methods for identifying which variant(s) of this gene is/are possessed by an individual.
  • NATl arylamine N-acetyltransferase
  • haplotype is the ordered combination of polymorphisms in the sequence of each form of a gene that exists in the population. Because haplotypes represent the variation across each form of a gene, they provide a more accurate and reliable measurement of genetic variation than individual polymorphisms. For example, while specific variations in gene sequences have been associated with a particular phenotype such as disease susceptibility (Roses AD supra; Ulbrecht M et al. 2000 Am JRespir Crit Care Med 161: 469-74) and drug response (Wolfe CR et al.
  • ⁇ AT1 ⁇ - acetyltransferase 1 (arylamine ⁇ -acetyltransferase) ( ⁇ AT1) gene or its encoded product.
  • ⁇ AT1 catalyzes the acetylation of arylamines and hydrazines, and is involved in the activation and detoxification of carcinogens.
  • NATl is mainly expressed in erythrocytes, bladder, lymphocytes and neural tissue, as well as in liver and intestine.
  • NATl also plays an endogenous role in the acetylation of the folate catabolite, p-aminobenzoyl-L-glutamate (pABGlu) to produce the major urinary product, N-acetyl-pABGlu (Smelt et al., Hum. Mol. Genet. 2000; 9: 1101-1107).
  • pABGlu p-aminobenzoyl-L-glutamate
  • the N-acetyltransferase -l(arylamine N-acetyltransferase) gene is located on chromosome 8p23.1-p21.3 and contains 1 exon that encodes a 290 amino acid protein.
  • Reference sequences for the NATl gene (Genaissance Reference No. 2517962; SEQ ID NO: 1), coding sequence (GenBank Accession No:NM_000662.1), and protein are shown in Figures 1, 2 and 3, respectively.
  • cytosine or thymine at a position corresponding to nucleotide 97, an adenine or thymi ⁇ e at a position corresponding to nucleotide position 401, a guanine or adenine at a position corresponding to nucleotide position 885, a guanine or adenine at a position corresponding to nucleotide position 899 and a thymine or guanine at a position corresponding to nucleotide position 1080.
  • polymorphisms at nucleotide positions 885 and 1080 result in amino acid variations of valine or isoleucine at amino acid position 149 (NATl* 11), and a serine or alanine at amino acid position 214 (NAT1*25) in Figure 3, respectively (Doll et al., Biochem. Biophys. Res. Commun. 1997; 233:584-591, SWISS-PROT.P18440).
  • NATl polymorphisms play an important role in susceptibility to lung cancer by influencing the acetylation of tobacco derived carcinogens.
  • Bouchardy et al. (Pharmacogenetics 1998; 8:291- 298) evaluated 150 lung cancer patients for genetic variants of NATl, all of whom were French Caucasian smokers. They found that subjects carrying the slow acetylator variant, NAT1*14, had the highest risk for lung cancer suggesting that this polymorphism modifies an individual's susceptibility to smoking-induced lung cancer.
  • polymorphic sites correspond to the following nucleotide positions in Figure 1: 97 (PS1), 163 (PS2), 288 (PS3), 405 (PS5), and 461 (PS6),
  • PS1 polymorphic sites
  • PS2 polymorphic sites
  • PS3 polymorphic sites
  • PS5 polymorphic sites
  • PS6 polymorphic sites
  • the polymo hisms at these sites are cytosine or thymine at PS1, thymine or adenine at PS2, guanine or adenine at PS3, adenine or thymine at PS5, thymine or guanine at PS6,.
  • the inventors have determined the identity of the alleles at these sites, as well as at the previously identified sites at nucleotide positions 401 (PS4),885 (PS7), 899 (PS8), 1000 (PS9) and 1080 (PS10), in a human reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: African descent, Asian, Caucasian and Hispanic/Latino. From this information, the inventors deduced a set of haplotypes and haplotype pairs for PS 1-10 in the NATl gene, which are shown below in Tables 5 and 4, respectively. Each of these NATl haplotypes defines a naturally-occurring isoform (also referred to herein as an "isogene") of the NATl gene that exists in the human population.
  • isogene also referred to herein as an "isogene
  • the invention provides a method, composition and kit for genotyping the NATl gene in an individual.
  • the genotyping method comprises identifying the nucleotide pair that is present at one or more polymorphic sites selected from the group consisting of PS1, PS2, PS3, PS5 and PS6 in both copies of the NATl gene from the individual.
  • a genotyping composition of the invention comprises an oligonucleotide probe or primer which is designed to specifically hybridize to a target region containing, or adjacent to, one of these novel NATl polymorphic sites.
  • a genotyping kit of the invention comprises a set of oligonucleotides designed to genotype each of these novel NATl polymorphic sites.
  • the genotyping kit comprises a set of oligonucleotides designed to genotype each of PS 1-10.
  • the genotyping method, composition, and kit are useful in determining whether an individual has one of the haplotypes in Table 4 below or has one of the haplotype pairs in Table 3 below.
  • the invention also provides a method for haplotyping the NATl gene in an individual.
  • the haplotyping method comprises determining, for one copy of the NATl gene, the identity of the nucleotide at one or more polymorphic sites selected from the group consisting of PS1, PS2, PS3, PS5 and PS6.
  • the haplotyping method comprises determining whether one copy of the individual's NATl gene is defined by one of the NATl haplotypes shown in Table 4, below, or a sub-haplotype thereof.
  • the haplotyping method comprises dete ⁇ nining whether both copies of the individual's NATl gene are defined by one of the NATl haplotype pairs shown in Table 3 below, or a sub-haplotype pair thereof.
  • the method for establishing the NATl haplotype or haplotype pair of an individual is useful for improving the efficiency and reliability of several steps in the discovery and development of drugs for treating diseases associated with NATl activity, e.g., lung cancer.
  • the haplotyping method can be used by the pharmaceutical research scientist to validate NATl as a candidate target for treating a specific condition or disease predicted to be associated with NATl activity. Determining for a particular population the frequency of one or more of the individual NATl haplotypes or haplotype pairs described herein will facilitate a decision on whether to pursue NATl as a target for treating the specific disease of interest. In particular, if variable NATl activity is associated with the disease, then one or more NATl haplotypes or haplotype pairs will be found at a higher frequency in disease cohorts than in appropriately genetically matched controls.
  • variable NATl activity has little, if any, involvement with that disease.
  • the pharmaceutical research scientist can, without a priori knowledge as to the phenotypic effect of any NATl haplotype or haplotype pair, apply the information derived from detecting NATl haplotypes in an individual to decide whether modulating NATl activity would be useful in treating the disease.
  • the claimed invention is also useful in screening for compounds targeting NATl to treat a specific condition or disease predicted to be associated with NATl activity. For example, detecting which of the NATl haplotypes or haplotype pairs disclosed herein are present in individual members of a population with the specific disease of interest enables the pharmaceutical scientist to screen for a compound(s) that displays the highest desired agonist or antagonist activity for each of the most frequent NATl isoforms present in the disease population.
  • the claimed haplotyping method provides the scientist with a tool to identify lead compounds that are more likely to show efficacy in clinical trials.
  • the method of haplotyping the NATl gene in an individual is also useful to control for genetically-based bias in the design of candidate drugs that target or are metabolized by NATl.
  • the pharmaceutical scientist of ordinary skill would be concerned that a favorable efficacy and/or side effect profile shown in a Phase II or Phase III trial may not be replicated in the general population if a higher (or lower) percentage of patients in the treatment group, compared to the general population, have a form of the NATl gene that makes them genetically predisposed to metabolize the drug more efficiently than patients with other forms of the NATl gene.
  • the pharmaceutical scientist can immediately reduce this potential for genetically-based bias in the results of clinical trials of drugs metabolized by or targeting NATl by practicing the claimed invention.
  • the pharmaceutical scientist can then assign that individual to the treatment or control group as appropriate to ensure that approximately equal frequencies of the different NATl haplotypes (or haplotype pairs) are represented in the two groups and/or the frequencies of different NATl haplotypes or haplotype pairs are similar to the frequencies in the general population.
  • the pharmaceutical scientist can more confidently rely on the information learned from the trial, without first determining the phenotypic effect of any NATl haplotype or haplotype pair.
  • the invention provides a method for identifying -an association between a trait and a NATl genotype, haplotype, or haplotype pair for one or more of the novel polymorphic sites described herein.
  • the method comprises comparing the frequency of the NATl genotype, haplotype, or haplotype pair in a population exhibiting the trait with the frequency of the NATl genotype or haplotype in a reference population. A higher frequency of the NATl genotype, haplotype, or haplotype pair in the trait population than in the reference population indicates the trait is associated with the NATl genotype, haplotype, or haplotype pair.
  • the trait is susceptibility to a disease, severity of a disease, the staging of a disease or response to a drug.
  • the NATl haplotype is selected from the haplotypes shown in Table 4, or a sub-haplotype thereof. Such methods have applicability in developing diagnostic tests and therapeutic treatments for lung cancer.
  • the invention provides an isolated polynucleotide comprising a nucleotide sequence which is a polymorphic variant of a reference sequence for the NATl gene or a fragment thereof.
  • the reference sequence comprises SEQ ID NO:l and the polymorphic variant comprises at least one polymorphism selected from the group consisting of thymine at PS1, adenine at PS2, adenine at PS3, thymine at PS5, and guanine at PS6.
  • the polymorphic variant comprises one or more additional polymorphisms selected from the group consisting of thymine at PS4, adenine at PS7, adenine at PS8, adenine at PS9 and guanine atPSlO.
  • a particularly preferred polymorphic variant is an isogene of the NATl gene.
  • a NATl isogene of the invention comprises cytosine or thymine at PS1, thymine or adenine at PS2, guanine or adenine at PS3, adenine or thymine at PS4, adenine or thymine at PS5, thymine or guanine at PS6, guanine or adenine at PS7, guanine or adenine at PS8, guanine or adenine at PS9 and thymine or guanine at PS 10.
  • the invention also provides a collection of NATl isogenes, referred to herein as a NATl genome anthology.
  • the invention provides a polynucleotide comprising a polymorphic variant of a reference sequence for a NATl cDNA or a fragment thereof.
  • the reference sequence comprises SEQ LD NO:2 (Fig.2) and the polymorphic cDNA comprises guanine at a position corresponding to nucleotide 21.
  • the polymorphic variant comprises one or more additional polymorphisms selected from the group consisting of adenine at a position corresponding to nucleotide 445, adenine at a position corresponding to nucleotide 459, adenine at a position corresponding to nucleotide 560 and guanine at a position corresponding to nucleotide 640.
  • a particularly preferred polymorphic cDNA variant comprises the coding sequence of a NATl isogene defined by haplotypes 2-7.
  • Polynucleotides complementary to these NATl genomic and cDNA variants are also provided by the invention. It is believed that polymorphic variants of the NATl-gene will be useful in studying the expression and function of NATl, and in expressing NATl protein for use in screening for candidate drugs to treat diseases related to NATl activity.
  • the invention provides a recombinant expression vector comprising one of the polymorphic genomic variants operably linked to expression regulatory elements as well as a recombinant host cell transformed or transfected with the expression.vector.
  • the recombinant vector and host cell may be used to express NATl for protein structure analysis and drug binding studies.
  • the present invention also provides nonhuman transgenic animals comprising one of the NATl polymorphic genomic variants described herein and methods for producing such animals.
  • the transgenic animals are useful for studying expression of the NATl isogenes in vivo, for in vivo screening and testing of drugs targeted against NATl protein, and for testing the efficacy of therapeutic agents and compounds for lung cancer in a biological system.
  • the present invention also provides a computer system for storing and displaying polymorphism data determined for the NATl gene.
  • the computer system comprises a computer processing unit; a display; and a database containing the polymorphism data.
  • the polymorphism data includes the polymorphisms, the genotypes and the haplotypes identified for the NATl gene in a reference population.
  • the computer system is capable of producing a display showing NATl haplotypes organized according to their evolutionary relationships.
  • Figure 1 illustrates a reference sequence for the NATl gene (Genaissance Reference No. 2517962; contiguous lines; SEQ LO NO:l), with the start and stop positions of each region of coding sequence indicated with a bracket ([ or ]) and the numerical position below the sequence and the polymorphic site(s) and polymorphism(s) identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymorphic site in the sequence.
  • Figure 2 illustrates a reference sequence for the NATl coding sequence (contiguous lines; SEQ LD NO:2), with the polymorphic site(s) and polymorphism(s) identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymorphic site in the sequence.
  • Figure 3 illustrates a reference sequence for the NATl protein (contiguous lines; SEQ LD NO:3), with the variant amino acid(s) caused by the polymorphism(s) of Figure 2 positioned.below the polymorphic site in the sequence.
  • the present invention is based on the discovery of novel variants of the NATl gene.
  • the inventors herein discovered 8 isogenes of the NATl gene by characterizing the NATl gene found in genomic DNAs isolated from an Index Repository that contains immortalized cell lines from one chimpanzee and 93 human individuals.
  • the human individuals included a reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: Caucasian (CA) (22 individuals), African descent (AF) (20 individuals), Asian (AS) (20 individuals), or Hispanic/Latino (HL) (17 individuals).
  • CA Caucasian
  • AF African descent
  • AS Asian
  • HL Hispanic/Latino
  • the Index Repository contains three unrelated indigenous American Indians (one from each of North, Central and South America), one three-generation Caucasian family (from the CEPH Utah cohort) and one two-generation African- American family.
  • the NATl isogenes present in the human reference population are defined by haplotypes for 10 polymorphic sites in the NATl gene, 5 of which are believed to be novel.
  • the NATl polymorphic sites identified by the inventors are referred to as PS1-10 to designate the order in which they are located in the gene (see Table 2 below), with the novel polymorphic sites referred to as PS1, PS2, PS3, PS5 and PS6.
  • the inventors herein Using the genotypes identified in the Index Repository for PS1-10 and the methodology described in the Examples below, the inventors herein also determined the pair of haplotypes for the NATl gene present in individual human members of this, repository.
  • the human genotypes and haplotypes found in the repository for the NATl gene include those shown in Tables 3 and 4, respectively.
  • the polymorphism and haplotype data disclosed herein are useful for validating whether NATl is a suitable target for drugs to treat lung cancer, screening for such drugs and reducing bias in clinical trials of such drugs.
  • Allele - A particular form of a genetic locus, distinguished from other forms by its particular nucleotide sequence.
  • Candidate Gene - A gene which is hypothesized to be responsible for a disease, condition, or the response to a treatment, or to be correlated with one of these.
  • Genotype An unphased 5 ' to 3 ' sequence of nucleotide pair(s) found at one or more polymorphic sites in a locus on a pair of homologous chromosomes in an individual.
  • genotype includes a full-genotype and or a sub-genotype as described below.
  • Sub-genotype The unphased 5' to 3' sequence of nucleotides seen at a subset of the known polymorphic sites in a locus on a pair of homologous chromosomes in a single individual.
  • Genotyping A process for determining a genotype of an individual.
  • Haplotype A 5' to 3' sequence of nucleotides found at one or more polymorphic sites in a locus on a single chromosome from a single individual.
  • haplotype includes a full- haplotype and/or a sub-haplotype as described below.
  • Full-haplotype The 5 ' to 3 ' sequence of nucleotides found at all known polymorphic sites in a locus on a single chromosome from a single individual.
  • Sub-haplotype The 5' to 3' sequence of nucleotides seen at a subset of the known polymorphic sites in a locus on a single chromosome from a single individual.
  • Haplotype pair The two haplotypes found for a locus in a single individual.
  • Haplotyping A process for determining one or more haplotypes in an individual and includes use of family pedigrees, molecular techniques and/or statistical inference.
  • Haplotype data Information concerning one or more of the following for a specific gene: a listing of the haplotype pairs in each individual in a population; a listing of the different haplotypes in a population; frequency of each haplotype in that or other populations, and any known associations between one or more haplotypes and a trait.
  • Isoform - A particular form of a gene, mRNA, cDNA or the protein encoded thereby, distinguished from other forms by its particular sequence and/or structure.
  • Isogene One of the isoforms of a gene found in a population. An isogene contains all of the polymorphisms present in the particular isoform of the gene.
  • Isolated - As applied to a biological molecule such as RNA, DNA, oligonucleotide, or protein, isolated means the molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term “isolated” is not intended to refer to a complete absence of such material or to absence of water, buffers, or salts, unless they are present in amounts that substantially interfere with the methods of the present invention.
  • Locus - A location on a chromosome or DNA molecule corresponding to a gene or a physical or phenotypic feature.
  • Naturally-occurring A term used to designate that the object it is applied to, e.g.,. naturally-occurring polynucleotide or polypeptide, can be isolated from a source in nature and which has not been intentionally modified by man.
  • Nucleotide pair The nucleotides found at a polymorphic site on the two copies of a chromosome from an individual.
  • phased As applied to a sequence of nucleotide pairs for two or more polymorphic sites in a locus, phased means the combination of nucleotides present at those polymorphic sites on a single copy of the locus is known.
  • PS Polymorphic site
  • Polymorphism The sequence variation observed in an individual at a polymorphic site. Polymorphisms include nucleotide substitutions, insertions, deletions and microsatellites and may, but need not, result in detectable differences in gene expression or protein function.
  • Polymorphism data Information concerning one or more of the following for a specific gene: location of polymorphic sites; sequence variation at those sites; frequency of polymorphisms in one or more populations; the different genotypes and/or haplotypes determined for the gene; frequency of one or more of these genotypes and/or haplotypes in one or more populations; any known associations) between a trait and a genotype or a haplotype for the gene.
  • Polymorphism Database A-collection of polymorphism data arranged in a systematic or methodical way and capable of being individually accessed by electronic or other means.
  • Polynucleotide - A nucleic acid molecule comprised of single ⁇ stranded RNA or DNA or comprised of complementary, double-stranded DNA.
  • Reference Population A group of subjects or individuals who are predicted to be representative of the genetic variation found in the general population.
  • the reference population represents the genetic variation in the population at a certainty level of at least 85%, preferably at least 90%, more preferably at least 95% and even more preferably at least 99%.
  • SNP Single Nucleotide Polymorphism
  • Subject A human individual whose genotypes or haplotypes or response to treatment or disease state are to be determined.
  • Treatment A stimulus administered internally, or externally to a subject.
  • Unphased - As applied to a sequence of nucleotide pairs for two or more polymorphic sites in a locus, unphased means the combination of nucleotides present at those polymorphic sites on a single copy of the locus is not known.
  • the invention also provides compositions and methods for detecting the novel NATl polymorphisms and haplotypes identified herein.
  • compositions comprise at least one NATl genotyping oligonucleotide.
  • a NATl genotyping oligonucleotide is a probe or primer capable of hybridizing to a target region that is located close to, or that contains, one of the novel polymorphic sites described herein.
  • the term "oligonucleotide” refers to a polynucleotide molecule having less than about 100 nucleotides.
  • a preferred oligonucleotide of the invention is 10 to 35 nucleotides long. More preferably, the oligonucleotide is between 15 and 30, and most preferably, between 20 and 25 nucleotides in length.
  • oligonucleotide may be ⁇ comprised of any phosphorylation state of ribonucleotides, deoxyribonucleotides, and acyclic nucleotide derivatives, and other functionally equivalent derivatives.
  • oligonucleotides may have a phosphate-free backbone, which may be comprised of linkages such as carboxymethyl, acetamidate, carbamate, polyamide (peptide nucleic acid (PNA)) and the like (Var a, R. in Molecular Biology and Biotechnology, A Comprehensive Desk Reference, Ed. R.
  • Oligonucleotides of the invention may be prepared by chemical synthesis using any suitable methodology known in the art, or may be derived from a biological sample, for example, by restriction digestion.
  • the oligonucleotides may be labeled, according to any technique known in the art, including use of radiolabels, fluorescent labels, enzymatic labels, proteins, haptens, antibodies, sequence tags and the like.
  • Genotyping oligonucleotides of the invention must be capable of specifically hybridizing to a target region of a NATl polynucleotide, i.e., a NATl isogene.
  • specific hybridization means the oligonucleotide forms an anti-parallel double-stranded structure with the target region under certain hybridizing conditions, while failing to form such a structure when incubated with a non-target region or a non-NATl polynucleotide under the same hybridizing conditions.
  • the oligonucleotide specifically hybridizes to the target region under conventional high stringency conditions.
  • oligonucleotide probes and primers suitable for detecting polymorphisms in the NATl gene using the polymorphism ihformation provided herein in conjunction with the known sequence information for the NATl gene and routine techniques.
  • a nucleic acid molecule such as an oligonucleotide or polynucleotide is " said to be a "perfect” or “complete” complement of another nucleic acid molecule if every nucleotide of one of the molecules is complementary to the nucleotide at the corresponding position of the other molecule.
  • a nucleic acid molecule is "substantially complementary” to another molecule if it hybridizes to that molecule with sufficient stability to remain in a duplex form under conventional low-stringency conditions. Conventional hybridization conditions are described, for example, by Sambrook J. et al., in Molecular Cloning, A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and by Haymes, B.D.
  • an oligonucleotide primer may have a non-complementary fragment at its 5 ' end, with the remainder of the primer being complementary to the target region.
  • non-complementary nucleotides may be interspersed into the oligonucleotide probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.
  • Preferred genotyping oligonucleotides of the invention are allele-specific oligonucleotides.
  • ASO allele-specific oKgonucleotide
  • allele-specificity will depend upon a variety of readily optimized stringency conditions, including salt and formamide concentrations, as well as temperatures for both the hybridization and washing steps.
  • Allele-specific oligonucleotides of the invention include ASO probes and ASO primers.
  • ASO probes which usually provide good discrimination between different alleles are those in which a central position of the oligonucleotide probe aligns with the polymorphic site in the target region (e.g., approximately the 7 th or 8 th position in a 15mer, the 8 th or 9 th position in a 16mer, and the 10 th or 11 th position in a 20mer).
  • An ASO primer of the invention has a 3 ' te ⁇ ninal nucleotide, or preferably a 3' penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present.
  • ASO probes and primers hybridizing to either the coding or noncoding strand are contemplated by the invention.
  • a preferred ASO probe for detecting NATl gene polymorphisms comprises a nucleotide sequence, listed 5 ' to 3', selected from the group consisting of:
  • CAGAAGAYGTTTATA (SEQ ID NO: 4) and its complement
  • AGAACCAWGAACAAG (SEQ ID NO: 5) and its complement
  • TAAA&TGWTTTGCTT (SEQ ID NO: 7) and its complement
  • a preferred ASO primer for detecting NATl gene polymorphisms comprises a nucleotide sequence, listed 5 ' to 3 ', selected from the group consisting of:
  • TATGTGTGTAAAARG (SEQ ID -NO: 13); ATTG A GAATTCYT (SEQ ID NO: 14);
  • TAA ⁇ GTAAAATGWT (SEQ ID NO: 15); AA ⁇ CGAA&GCAAAWC (SEQ ID NO: 16);
  • TTGAAGCATATCTKG SEQ ID NO: 17
  • AGCCAATTCTTTCMA SEQ ID NO: 18
  • genotyping oligonucleotides of the invention hybridize to a target region located one to several nucleotides downstream of one of the novel polymorphic sites identified herein. Such oligonucleotides are useful in polymerase-mediated primer extension methods for detecting one of the novel polymorphisms described herein and therefore such genotyping oligonucleotides are referred to herein as "primer-extension oligonucleotides”.
  • the 3 '- terminus of a primer-extension oligonucleotide is a deoxynuclocatingide complementary to the nucleotide located immediately adjacent to the polymorphic site.
  • a particularly preferred oligonucleotide primer for detecting NATl gene polymorphisms by primer extension terminates in a nucleotide sequence, listed 5' to 3', selected from the group consisting of:
  • CATCAGAAGA (SEQ ID NO: 19) ; GCTTATAAAC (SEQ ID NO:20);
  • AAGAGAACCA SEQ ID NO: 21
  • CAGCTTGTTC SEQ ID NO:22
  • GTGTGTAAAA (SEQ ID NO: 23) ; GTATGAATTC (SEQ ID NO:24);
  • AAGTAAAATG (SEQ ID NO: 25) ; CGAAAGCAAA (SEQ ID NO:26);
  • AAGCATATCT SEQ ID NO:27
  • CAAITCTTTC SEQ ID NO:28
  • a composition contains two or more differently labeled genotyping oligonucleotides for simultaneously probing the identity of nucleotides at two or more polymorphic sites. It is also contemplated that primer compositions may contain two or more sets of allele- specific primer pairs to allow simultaneous targeting and amplification of two or more regions containing a polymorphic site.
  • NATl genotyping oligonucleotides of the invention may also be immobilized on or synthesized on a solid surface such* s a microchip, bead, or glass slide (see, e.g., WO 98/20020 and WO 98/20019).
  • Such immobilized genotyping oligonucleotides may be used in a variety of polymorphism detection assays, including but not limited to probe hybridization and polymerase extension assays.
  • Immobilized NATl genotyping oligonucleotides of the invention may comprise an ordered array of oligonucleotides designed to rapidly screen a DNA sample for polymo ⁇ hisms in multiple genes at the same time.
  • the invention provides a kit comprising at least two genotyping oligonucleotides packaged in separate containers.
  • the kit may also contain other components such as hybridization buffer (where the oligonucleotides are to be used as a probe) packaged in a separate container.
  • the kit may contain, packaged in separate containers, a polymerase and a reaction buffer optimized for primer extension mediated by the polymerase, such as PCR.
  • NATl genotype and “NATl haplotype” mean the genotype or haplotype contains the nucleotide pair or nucleotide, respectively, that is present at one or more of the novel polymo ⁇ hic sites described herein and may optionally also include the nucleotide pair or nucleotide present at one or more additional polymo ⁇ hic sites in the NATl gene.
  • the additional polymo ⁇ hic sites may be currently known polymo ⁇ hic sites or sites that are subsequently discovered.
  • One embodiment of the genotyping method involves isolating from the individual a nucleic acid sample comprising the two copies of the NATl gene, or a fragment thereof, that are present in the individual, and determining the identity of the nucleotide pair at one or more polymo ⁇ hic sites selected from the group consisting of PS1, PS2, PS3, -PS5 and PS6 in the two copies to assign a NATl genotype to the individual.
  • the two "copies" of a gene in an individual may be the same allele or may be different alleles.
  • the identity of the nucleotide pair at one or more of the polymo ⁇ hic ' sites selected from the group consisting of PS4 and PS7-PS10 is also determined.
  • the genotyping method comprises determining the identity of the nucleotide pair at each of PS1-10.
  • the nucleic acid sample is isolated from a biological sample taken from the individual, such as a blood sample or tissue sample.
  • tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair.
  • the nucleic acid sample may be comprised of genomic DNA, mRNA, or cDNA and, in the latter two cases, the biological sample must be obtained from a tissue in which the NATl gene is expressed.
  • mRNA or cDNA preparations would not be used to detect polymo ⁇ hisms located in introns or in 5 ' and 3 ' untranslated regions. If a NATl gene fragment is isolated, it must contain the polymo ⁇ hic site(s) to be genotyped.
  • One embodiment of the haplotyping method comprises isolating from the individual a nucleic acid sample containing only one of the two copies of the NATl gene, or a fragment thereof, that is present in the individual and determining in that copy the identity of the nucleotide at one or more polymo ⁇ hic sites selected from the group consisting of PS1, PS2,, PS3, PS5 and PS6 in that copy to assign a NATl haplotype to the individual.
  • the nucleic acid may be isolated using any method capable of separating the two copies of the NATl gene or fragment such as one of the methods described above for preparing NATl isogenes, with targeted in vivo cloning being the preferred approach.
  • the haplotyping method also comprises identifying the nucleotide at one or more polymo ⁇ hic sites selected from the group consisting of PS4 and PS7-PS10. In a particularly preferred embodiment, the nucleotide at each of PS1-10 is identified.
  • the haplotyping method comprises determining whether ah individual has one or more of the NATl haplotypes shown in Table 4. This can be accomplished by identifying, for one or both copies of the individual's NATl gene, the phased sequence of nucleotides present at each of PS 1- 10.
  • the present invention also contemplates that typically only a subset of PS1-10 will need to be directly examined to assign to an individual one or more of the haplotypes shown in Table 4. This is because at least one polymo ⁇ hic site in a gene is frequently in strong linkage disequilibrium with one or more other polymo ⁇ hic sites in that gene (Drysdale, CM et al.
  • a NATl haplotype pair is determined for an individual by identifying the phased sequence of nucleotides at one or more polymo ⁇ hic sites selected from the group consisting of PS1, PS2, PS3, PS5 and PS6 in each copy of the NATl gene that is present in the individual.
  • the haplotyping method comprises identifying the phased sequence of nucleotides at each of PS 1-10 in each copy of the NATl gene.
  • the identifying step is preferably performed with each copy of the gene being placed in separate containers. However, it is also envisioned that if the two copies are labeled with different tags, or are otherwise separately distinguishable or identifiable, it .
  • first and second copies of the gene are labeled with different first and second fluorescent dyes, respectively, and an allele-specific oligonucleotide labeled with yet a third different fluorescent dye is used to assay the polymo ⁇ hic site(s), then detecting a combination of the first and third dyes would identify the polymo ⁇ hism in the first gene copy while detecting a combination of the second and third dyes would identify the polymo ⁇ hism in the second gene copy.
  • the identity of a nucleotide (or nucleotide pair) at a polymo ⁇ hic site(s) may be determined by amplifying a target region(s) containing the polymo ⁇ hic site(s) directly from one or both copies of the NATl gene, or a fragment thereof, and the sequence of the amplified region(s) determined by conventional methods. It will be readily appreciated by the skilled artisan that only one nucleotide will be detected at a polymo ⁇ hic site in individuals who are homozygous at that site, while two different nucleotides will be detected if the individual is heterozygous for that site.
  • the polymo ⁇ hism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification.
  • a site may be positively determined to be either guanine or cytosine for an individual homozygous at that site, or both guariine and cytosine, if the individual is heterozygous at that site.
  • the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).
  • the target region(s) may be amplified using any oligonucleotide-directed amplification method, including but not limited to polymerase chain reaction (PCR) (U.S. Patent No. 4,965,188), ligase chain reaction (LCR) (Barany et al., Proc. Natl. Acad. Sci. USA 88:189-193, 1991; WO90/01069), and oligonucleotide ligation assay (OLA) (Landegren et al, Science 241:1077-1080, 1988).
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • OLA oligonucleotide ligation assay
  • nucleic acid amplification procedures may be used to amplify the target region including transcription-based amplification systems (U.S. Patent No. 5,130,238; EP 329,822; U.S. Patent No. 5,169,766, WO89/06700) and isothermal methods (Walker et al., Proc. Natl. Acad. Sci. USA 89:392-396, 1992).
  • a polymo ⁇ hism in the target region may also be assayed before or after amplification using one of several hybridization-based methods known in the art.
  • allele-specific oligonucleotides are utilized in performing such methods.
  • the allele-specific oligonucleotides may be used as differently labeled probe pairs, with one member of the pair showing a perfect match to one variant of a target sequence and the other member showing a perfect match to a different variant.
  • more than one polymo ⁇ hic site may be detected at once using a set of allele- specific oligonucleotides or oligonucleotide pairs.
  • the members of the set have melting temperatures within 5°C, and more preferably within 2°C, of each other when hybridizing to each of the polymo ⁇ hic sites being detected.
  • Hybridization of an allele-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution, or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin, salt bridges, hydrophobic interactions, chemical linkages, UV cross- linking baking, etc. Allele-specific oligonucleotides may be synthesized directly on the solid support or attached to the solid support subsequent to synthesis.
  • Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads.
  • the solid support may be treated, coated or derivatized to facilitate the immobilization of the allele-specific oligonucleotide or target nucleic acid.
  • the genotype or haplotype for the NATl gene of an individual may also be determined by hybridization of a nucleic acid sample containing one or both copies of the gene, or fragments) thereof, to nucleic acid arrays and subarrays such as described in WO 95/11995.
  • the arrays would contain a battery of allele-specific oligonucleotides representing each of the polymo ⁇ hic sites to be included in the genotype or haplotype.
  • polymo ⁇ hisms may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al., Proc. Natl. Acad. Sci. USA 82:7575, 1985; Meyers et al, Science 230:1242, 1985) and proteins which recognize nucleotide mismatches, such as the E. coli mutS protein (Modrich, P. Ann. Rev. Genet. 25:229-253, 1991).
  • riboprobes Winter et al., Proc. Natl. Acad. Sci. USA 82:7575, 1985; Meyers et al, Science 230:1242, 1985
  • proteins which recognize nucleotide mismatches such as the E. coli mutS protein (Modrich, P. Ann. Rev. Genet. 25:229-253, 1991).
  • variant alleles can be identified by single strand conformation polymo ⁇ hism (SSCP) analysis (Orita et al., Genomics 5:874-879, 1989; Humphries et al., in Molecular Diagnosis of Genetic Diseases, R. Elles, ed., pp. 321-340, 1996) or denaturing gradient gel electrophoresis (DGGE) (Wartell et al., Nucl. Acids Res. 18:2699-2706, 1990; Sheffield et al., Proc. Natl. Acad. Sci. USA 86:232-236, 1989).
  • SSCP single strand conformation polymo ⁇ hism
  • DGGE denaturing gradient gel electrophoresis
  • a polymerase-mediated primer extension method may also be used to identify the polymo ⁇ hism(s).
  • Several such methods have been described in the patent and scientific literature and include the "Genetic Bit Analysis” method (W092/15712) and the ligase/polymerase mediated genetic bit analysis (U.S. Patent 5,679,524. Related methods are disclosed in W091/02087, WO90/09455, W095/17676; U.S. Patent Nos. 5,302,509, and 5,945,283. Extended primers containing a polymo ⁇ hism may be detected by mass spectrometry as described in U.S. Parent No. 5,605,798.
  • Another primer extension method is allele-specific PCR (Ruano et al., Nucl.
  • the identity of the allele(s) present at any of the novel polymo ⁇ hic sites described herein may be indirectly determined by genotyping another pplymo ⁇ hic site that is in linkage disequilibrium with the polymo ⁇ hic site that is of interest.
  • an individual's NATl haplotype pair is predicted from its NATl genotype using information on haplotype pairs known to exist in a reference population.
  • the haplotyping prediction method comprises identifying a NATl genotype for the individual at two or more NATl polymo ⁇ hic sites described herein, enumerating all possible haplotype pairs which are consistent with the genotype, accessing data containing NATl haplotype pairs identified in a reference population, and assigning a haplotype pair to the individual that is consistent with the data.
  • the reference haplotype pairs include the NATl haplotype pairs shown in Table 4.
  • the reference population should be composed of randomly-selected individuals representing the major ethnogeographic groups of the world.
  • a preferred reference population allows the detection of any haplotype whose frequency is at least 10% with about 99% certainty and comprises about 20 unrelated individuals from each of the four population groups named above.
  • a particularly preferred reference population includes a 3- generation family representing one or more of the four population groups to serve as controls for checking quality of haplotyping procedures.
  • the haplotype frequency data for each ethnoge ⁇ graphic group is examined to determine whether it is consistent with Hardy- Weinberg equilibrium.
  • a statistically significant difference between the observed and expected haplotype frequencies could be due to one or more factors including significant inbreeding in the population group, strong selective pressure on the gene, sampling bias, and/or errors in the genotyping process. If large deviations from Hardy- Weinberg equilibrium are observed in an ethnogeographic group, the number of individuals in that group can be increased to see if the deviation is due to a sampling bias. If a larger sample size does not reduce the difference between observed and expected haplotype pair frequencies, then one may wish to consider haplotyping the individual using a direct haplotyping method such as, for example, CLASPER SystemTM technology (U.S. Patent No. 5,866,404), single molecule dilution, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996).
  • CLASPER SystemTM technology U.S. Patent No. 5,866,404
  • single molecule dilution single molecule dilution
  • the assigning step involves performing the following analysis. First, each of the possible haplotype pairs is compared to the haplotype pairs in the reference population. Generally, only one of the haplotype pairs in the reference population matches a possible haplotype pair and that pair is assigned to the individual. Occasionally, only one haplotype represented in the reference haplotype pairs is consistent with a possible haplotype pair for an individual, and in such cases the individudl is assigned a haplotype pair containing this known haplotype and a new haplotype derived by subtracting the known haplotype from the possible haplotype pair.
  • the haplotype pair in an individual may be predicted from the individual's genotype for that gene using reported methods (e.g., Clark et al. 1990 Mol Bio Evol 7:111-22) or through a commercial haplotyping service such as offered by Genaissance Pharmaceuticals, Inc. (New Haven, CT).
  • a commercial haplotyping service such as offered by Genaissance Pharmaceuticals, Inc. (New Haven, CT).
  • the individual is preferably haplotyped using a direct molecular haplotyping method such as, for example, CLASPER System TM technology (U.S. Patent No.
  • the invention also provides a method for determining the frequency of a NATl genotype, haplotype, or haplotype pair in a population.
  • the method comprises, for each member of the population, determining the genotype or the haplotype pair for the novel NATl polymo ⁇ hic sites described herein, and calculating the frequency any particular genotype, haplotype, or haplotype pair is found in the population.
  • the population may be a reference population, a family population, a same sex population, a population group, or a trait population (e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment).
  • a trait population e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment.
  • frequency data for NATl genotypes, haplotypes, and/or haplotype pairs are determined in a reference population and used in a method for identifying an association between a trait and a NATl genotype, haplotype, or haplotype pair.
  • the trait may be any detectable phenotype, including but not limited to susceptibility to a disease or response to a treatment.
  • the method involves obtaining data on the frequency of the genotype(s), haplotype(s), or haplotype pair(s) of interest in a reference population as well as in a population exhibiting the trait.
  • Frequency data for one or both of the reference and trait populations may be obtained by genotyping or haplotyping each individual in the populations using one of the methods described above.
  • the haplotypes for the trait population may be determined directly or, alternatively, by the predictive genotype to haplotype approach described above.
  • the frequency data for the reference and/or trait populations is obtained by accessing previously determined frequency data, which may be in written or electronic form.
  • the frequency data may be present in a database that is accessible by a computer. Once the frequency data is obtained, the frequencies of the genotype(s), haplotype(s), or haplotype pair(s) of interest in the reference and trait populations are compared. In a preferred embodiment, the frequencies of all genotypes, haplotypes,' and/or haplotype pairs observed in the populations are compared.
  • the trait is predicted to be associated with that NATl genotype, haplotype or haplotype pair.
  • the NATl genotype, haplotype, or haplotype pair being compared in the trait and reference populations is selected from the full-genotypes and full- haplotypes shown in Tables 4 and 5, or from sub-genotypes and sub-haplotypes derived from these genotypes and haplotypes.
  • the trait of interest is a clinical response exhibited by a patient to some therapeutic treatment, for example, response to a drug targeting NATl or response to a therapeutic treatment for a medical condition.
  • medical condition includes but is not limited to any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly identified diseases and other disorders.
  • clinical response means any or all of the following: a quantitative measure of the response, no response, and adverse response (i.e., side effects).
  • clinical population In order to deduce a correlation between clinical response to a treatment and a NATl genotype, haplotype, or haplotype pair, it is necessary to obtain data on the clinical responses exhibited by a population of individuals who received the treatment, hereinafter the "clinical population".
  • This clinical data may be obtained by analyzing the results of a clinical trial that has already been run and or the clinical data may be obtained by designing and carrying out one or more new clinical trials.
  • the term "clinical trial” means any research study designed to collect clinical data on responses to a particular treatment, and includes but is not limited to phase I, phase II and phase IH clinical trials. Standard methods are used to define the patient population and to enroll subjects.,
  • the individuals included in the clinical population have been graded for the existence of the medical condition of interest. This is important in cases where the symptom(s) being presented by the patients can be caused by more than one underlying condition, and where treatment of the underlying conditions are not the same. An example of this would be where patients experience breathing difficulties that are due to either asthma or respiratory infections. If both sets were treated with an asthma medication, there would be a spurious group of apparent non- responders that did not actually have asthma. These people would affect the ability to detect any correlation between haplotype and treatment outcome.
  • This grading of potential patients could employ a standard physical exam or one or more lab tests. Alternatively, grading of patients could use haplotyping for situations where there is a strong correlation between haplotype pair and disease susceptibility or severity.
  • the therapeutic treatment of interest is administered to each individual in the trial population and each individual's response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups (e.g., low, medium, high) made up by the various responses.
  • the NATl gene for each individual in the trial population is genotyped and/or haplotyped, which may be done before or after administering the treatment.
  • correlations between individual response and NATl genotype or haplotype content are created. Correlations may be produced in several ways. In one method, individuals are grouped by their NATl genotype or haplotype (or haplotype pair) (also referred to as a polymo ⁇ hism group), and then the averages and standard deviations of clinical responses exhibited by the members of each polymo ⁇ hism group are calculated.
  • a second method for finding correlations between NATl haplotype content and clinical responses uses predictive models based on error-minimizing optimization algorithms.
  • One of many possible optimization algorithms is a genetic algorithm (R. Judson, "Genetic Algorithms and Their Uses in Chemistry” in Reviews in Computational Chemistry, Vol. 10, pp. 1-73, K. B. Lipkowitz and D. B. Boyd, eds. (VCH Publishers, New York, 1997).
  • Simulated annealing Press et al., "Numerical Recipes in C: The Art of Scientific Computing", Cambridge University Press (Cambridge) 1992, Ch. 10), neural networks (E. Rich and K.
  • Correlations may also be analyzed using analysis of variation (ANOVA) techniques to determine how much of the variation in the clinical data is explained by different subsets of the polymo ⁇ hic sites in the NATl gene.
  • ANOVA analysis of variation
  • PCT/US00/17540 ANOVA is used to test hypotheses about whether a response variable is caused by or correlated with one or more traits or variables that can be measured (Fisher and vanBelle, si ⁇ ra, Ch. 10).
  • a mathematical model may be readily constructed by the skilled artisan that predicts clinical response as a function of NATl genotype or haplotype content.
  • the model is validated in one or more follow-up clinical trials designed to test the model.
  • the identification of an association between a clinical response and a genotype or haplotype (or haplotype pair) for the NATl gene may be the basis for designing a diagnostic method to determine those individuals who will or will not respond to the treatment, or alternatively, will respond at a lower level and thus may require more treatment, i.e., a greater dose of a drug.
  • the diagnostic method may take one of several forms: for example, a direct DNA test (i.e., genotyping or haplotyping one or more of the polymo ⁇ hic sites in the NATl gene), a serological test, or a physical exam measurement.
  • a direct DNA test i.e., genotyping or haplotyping one or more of the polymo ⁇ hic sites in the NATl gene
  • serological test i.e., a serological test
  • a physical exam measurement i.e., a physical exam measurement.
  • this diagnostic method uses the predictive haplotyping method described above.
  • the invention provides an isolated polynucleotide comprising a polymo ⁇ hic variant of the NATl gene or a fragment of the gene which contains at least one of the novel polymo ⁇ hic sites described herein.
  • the nucleotide sequence of a variant NATl gene is identical to the reference genomic sequence for those portions of the gene examined, as described in the Examples below, except that it comprises a different nucleotide at one or more of the novel polymo ⁇ hic sites PSl, PS2, PS3, PS5 and PS6, and may also comprise one or more additional polymo ⁇ hisms selected from the group consisting of thymine at PS4, adenine at PS7, adenine at PS8, adenine at PS9 and guanine at PS10.
  • nucleotide sequence of a variant fragment of the NATl gene is identical to the corresponding portion of the reference sequence except for having a different nucleotide at one or more of the novel polymo ⁇ hic sites described herein.
  • the invention specifically does not include polynucleotides comprising a nucleotide sequence identical to the reference sequence of the NATl gene, which is defined by haplotype 1, (or other reported NATl sequences) or to portions of the reference sequence (or other reported NATl sequences), except for genotyping oligonucleotides as described below.
  • polymo ⁇ hism in a variant gene or fragment is identified by aligning its sequence against SEQ ID NO:l.
  • the polymo ⁇ hism is selected from the group consisting of thymine at PSl, adenine at PS2, adenine at PS3, thymine at PS5, and guanine at PS6.
  • the polymo ⁇ hic variant comprises a natarally-occurring isogene of the NATl gene which is defined by any one of haplotypes 2-7 shown in Table 4 below.
  • Polymo ⁇ hic variants of the invention may be prepared by isolating a clone containing the NATl gene from a human genomic library.
  • the clone may be sequenced to determine the identity of the nucleotides at the novel polymo ⁇ hic sites described herein. Any particular variant claimed herein could be prepared from this clone by performing in vitro mutagenesis using procedures well- known in the art.
  • NATl isogenes may be isolated using any method that allows separation of the two "copies" of the NATl gene present in an individual, which, as readily understood by the skilled artisan, may be the same allele or different alleles. Separation methods include targeted in vivo cloning (TIVC) in yeast as described in WO 98/01573, U.S. Patent No. 5,866,404, and U.S. Patent No. 5,972,614. Another method, which is described in U.S. Patent No. 5,972,614, uses an allele specific oligonucleotide in combination with primer extension and exonuclease degradation to generate hemizygous DNA targets.
  • TIVC targeted in vivo cloning
  • Another method which is described in U.S. Patent No. 5,972,614, uses an allele specific oligonucleotide in combination with primer extension and exonuclease degradation to generate hemizygous DNA targets.
  • the invention also provides NATl genome anthologies, which are collections of NATl isogenes found in a given population.
  • the population may be any group of at least two individuals, including but not limited to a reference population, a population group, a family population, a clinical population, and a same sex population.
  • a NATl genome anthology may comprise individual NATl isogenes stored in separate containers such as microtest tubes, separate wells of a microtitre plate and the like. Alternatively, two or more groups of the NATl isogenes in the anthology may be stored in separate containers.
  • a preferred NATl genome anthology of the invention comprises a set of isogenes defined by the haplotypes shown in Table 4 below.
  • An isolated polynucleotide containing a polymo ⁇ hic variant nucleotide sequence of the invention may be operably linked to one or more expression regulatory elements in a recombinant expression vector capable of being propagated and expressing the encoded NATl protein in a prokaryotic or a eukaryotic host cell.
  • expression regulatory elements which may be used include, but are not limited to, the lac system, operator and promoter regions of phage lambda, yeast promoters, and promoters derived from vaccinia virus, adenovirus, retroviruses, or SV40.
  • regulatory elements include, but are not limited to, appropriate leader sequences, termination codons, polyadenylation signals, and other sequences required for the appropriate transcription and subsequent translation of the nucleic acid sequence in a given host cell.
  • the expression vector contains any additional elements necessary for its transfer to and subsequent replication in the host cell. Examples of such elements include, but are not limited to, origins of replication and selectable markers.
  • Such expression vectors are commercially available or are readily constructed using methods known to those in the art (e.g., F. Ausubel et al., 1987, in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York).
  • Host cells which may be used to express the variant NATl sequences of the invention include, but are not limited to, eukaryotic and mammalian cells, such as animal, plant, insect and yeast cells, and prokaryotic cells, such as E. coli, or algal cells as known in the art.
  • the recombinant expression vector may be introduced into the host cell using any method known to those in the art including, but not limited to, microinjection, electroporation, particle bombardment, transduction, and transfection using DEAE-dextran, lipofection, or calcium phosphate (see e.g., Sambrook et al. (1989) in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York).
  • eukaryotic expression vectors that function in eukaryotic cells, and preferably mammalian cells, are used.
  • Non-limiting examples of such vectors include vaccinia virus vectors, adenovirus vectors, he ⁇ es virus vectors, and baculovirus transfer vectors.
  • Preferred eukaryotic cell lines include COS cells, CHO cells, HeLa cells, NIH/3T3 cells, and embryomc stem cells (Thomson, J. A. et al., 1998 Science 282: 1145-1147).
  • Particularly preferred host cells are mammalian cells.
  • NATl mRNAs varying from each other at any polymo ⁇ hic site retained in the spliced and processed mRNA molecules.
  • These mRNAs can be used for the preparation of a NATl cDNA comprising a nucleotide sequence which is a polymo ⁇ hic variant of the NATl reference coding sequence shown in Figure 2.
  • the invention also provides NATl mRNAs and corresponding cDNAs which comprise a nucleotide sequence that is identical to SEQ LD NO:2 (Fig.
  • a particularly preferred polymo ⁇ hic cDNA variant comprises the coding sequence of a NATl isogene defined by haplotypes 2-7.
  • Fragments of these variant mRNAs and cDNAs are included in the scope of the invention, provided they contain the novel polymo ⁇ hism described herein.
  • the invention specifically excludes polynucleotides identical to previously identified and characterized NATl cDNAs and fragments thereof.
  • Polynucleotides comprising a variant RNA or DNA sequence may be isolated from a biological sample using well-known molecular biological procedures or may be chemically synthesized.
  • a polymo ⁇ hic variant of a NATl gene fragment comprises at least one novel polymo ⁇ hism identified herein and has a length of at least 10 nucleotides and* may range up to the full length of the gene.
  • such fragments are between 100 and 3000 nucleotides in length, and more preferably between 200 and 2000 nucleotides in length, and most preferably between 500 and 1000 nucleotides in length.
  • nucleic acid molecules containing the NATl gene may be complementary double stranded molecules and thus reference to a particular site on the sense strand refers as well to the corresponding site on the complementary antisense strand.
  • reference may be made to the same polymo ⁇ hic site on either strand and an oligonucleotide may be designed to hybridize specifically to either strand at a target region containing the polymo ⁇ hic site.
  • the invention also includes single-stranded polynucleotides which are complementary to the sense strand of the NATl genomic variants described herein.
  • Polynucleotides comprising a polymo ⁇ hic gene variant or fragment may be useful for therapeutic pu ⁇ oses.
  • an expression vector encoding the isoform may be administered to the patient.
  • the patient may be one who lacks the NATl isogene encoding that isoform or may already have at least one copy of that isogene.
  • NATl isogene may be turned off by transforming a targeted organ, tissue or cell population with an expression vector that expresses high levels of untranslatable mRNA for the isogene.
  • oligonucleotides directed against the regulatory regions (e.g., promoter, introns, enhancers, 3' untranslated region) of the isogene may block transcription. Oligonucleotides targeting the transcription initiation site, e.g., between positions -10 and +10 from the start site are preferred.
  • inhibition of transcription can be achieved using oligonucleotides that base- pair with region(s) of the isogene DNA to form triplex DNA (see e.g., Gee et al. in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y., 1994).
  • Antisense oligonucleotides may also be designed to block translation of NATl mRNA transcribed from a particular isogene. It is also contemplated that ribozymes may be designed that can catalyze the specific cleavage of NATl mRNA transcribed from a particular isogene.
  • the oligonucleotides may be delivered to a target cell or tissue by expression from a vector introduced into the cell or tissue in vivo or ex vivo.
  • the oligonucleotides may be formulated as a pharmaceutical composition for administration to the patient: Oligoribonucleptides and/or oligodeoxynucleotides intended for use as antisense oligonucleotides may ' be modified to increase stability and half-life.
  • Possible modifications include, but are not limited to phosphorothioate or 2' O-methyl linkages, and the inclusion of nontraditional bases such as inosine and queosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytosine, guanine, thymine, and uracil which are not as easily recognized by endogenous nucleases.
  • Effect(s) of the polymo ⁇ hisms identified herein on expression of NATl may be investigated by preparing recombinant cells and/or nonhuman recombinant organisms, preferably recombinant animals, containing a polymo ⁇ hic variant of the NATl gene.
  • expression includes but is not limited to one or more of the following: transcription of the gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce mature mRNA; mRNA stability; translation of the mature mRNA into NATl protein (including codon usage and tRNA availability); and glycosylation and/or other modifications of the translation product, if required for proper expression and function.
  • the desired NATl isogene may be introduced into the cell in a vector such that the isogene remains extrachromosomal. In such a situation, the gene will be expressed by.the cell from the extrachromosomal location.
  • the NATl isogene is introduced into a cell in such a way that it recombines with the endogenous NATl gene present in the cell. Such recombination requires the occurrence of a double recombination event, thereby resulting in the desired NATl gene polymo ⁇ hism.
  • Vectors for the introduction of genes both for recombination and for extrachromosomal maintenance are known in the art, and any suitable vector or vector construct may be used in the invention. Methods such as electroporation, particle bombardment, calcium phosphate co-precipitation and viral transduction for introducing DNA into cells are known in the art; therefore, the choice of method may lie with the competence and preference of the skilled practitioner.
  • Examples of cells into which the NATl isogene may be introduced include, but are not limited to, continuous culture cells, such as COS, NTH/3T3, and primary or culture cells of the relevant tissue type, i.e., they express the NATl isogene. Such recombinant cells can be used to compare the biological activities of the different protein variants.
  • Recombinant nonhuman organisms i.e., transgenic animals, expressing a variant NATl gene are prepared using standard procedures known in the art.
  • a construct comprising the variant gene is introduced into a nonhuman animal or an ancestor of the animal at an embryonic stage, i.e., the one-cell stage, or generally not later than about the eight-cell stage.
  • Transgenic animals carrying the constructs of the invention can be made by several methods known to those having skill in the art.
  • One method involves transfecting into the embryo a retrovirus constructed to contain one or more insulator elements, a gene or genes of interest, and other components known to those skilled in the art to provide a complete shuttle vector harboring the insulated gene(s) as a transgene, see e.g., U.S. Patent No. 5,610,053.
  • Another method involves directly injecting a transgene into the embryo.
  • a third method involves the use of embryonic stem cells. Examples of animals into which the NATl isogenes may be introduced include, but are not limited to, mice, rats, other rodents, and nonhuman primates (see "The Introduction of Foreign Genes into Mice" and the cited references therein, In: Recombinant DNA, Eds. J.D. Watson, M.
  • Transgenic animals stably expressing a human NATl isogene and producing human NATl protein can be used as biological models for studying diseases related to abnormal NATl expression and/or activity, and for screening and assaying various candidate drugs, compounds, and treatment regimens to reduce the symptoms or effects of these diseases.
  • compositions for treating disorders affected by expression or function of a novel NATl isogene described herein.
  • the pharmaceutical composition may comprise any of the following active ingredients: a polynucleotide comprising one of these novel NATl isogenes; an antisense oligonucleotide directed against one of the novel NATl isogenes, a polynucleotide encoding such an antisense oligonucleotide, or another compound which inhibits expression of a novel NATl isogene described herein.
  • the composition contains the active ingredient in a therapeutically effective amount.
  • composition also comprises a pharmaceutically acceptable carrier, examples of which include, but are not limited to, saline, buffered saline, dextrose, and water.
  • a pharmaceutically acceptable carrier examples of which include, but are not limited to, saline, buffered saline, dextrose, and water.
  • Those skilled in the art may employ a formulation most suitable for the active ingredient, whether it is a polynucleotide, oligonucleotide, protein, peptide or small molecule antagonist.
  • the pharmaceutical composition may be administered alone or in combination with at least one other agent, such as a stabilizing compound.
  • Administration of the pharmaceutical composition may be by any number of routes including, but not limited to oral, intravenous, intramuscular, intra-arteriaL intramedullary, intrathecal, intraventricular, intradermal, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).
  • the dose can be estimated initially either in cell culture assays or in animal models.
  • the animal model may also be used to determine the appropriate concentration range and route of administration.
  • Such information can then be used to determine useful doses and routes for administration in humans.
  • the exact dosage will be determined by the practitioner, in light of factors relating to the patient requiring treatment, including but not limited to severity of the disease state, general health, age, weight and gender of the patient, diet, time and frequency of administration, other drugs being taken by the patient, and tolerance/response to the treatment.
  • any or all analytical and mathematical operations involved in practicing the methods of the present invention may be implemented by a computer.
  • the computer may execute a program that generates views (or screens) displayed on a display device and with which the user can interact to view and analyze large amounts of information relating to the NATl gene and its genomic variation, including chromosome location, gene structure, and gene family, gene expression data, polymo ⁇ hism data, genetic sequence data, and clinical data population data (e.g., data on ethnogeographic origin, clinical responses, genotypes, and haplotypes for one or more populations).
  • the NATl polymo ⁇ hism data described herein may be stored as part of a relational database (e.g., an instance of an Oracle database or a set of ASCII flat files).
  • polymo ⁇ hism data may be stored on the computer's hard drive or may, for example, be stored on a CD-ROM or on one or more other storage devices accessible by the computer.
  • the data may be stored on one or more databases in communication with the computer via a network.
  • EXAMPLE 1 This example illustrates examination of various regions of the NATl gene for polymo ⁇ hic sites.
  • the following target regions of the NATl gene were amplified using PCR primer pairs.
  • the primers used for each region represented below by providing the nucleotide positions of their and final nucleotides, which correspond to positions in Figure 1.
  • Amplification profile 97°C - 2 min. 1 cycle
  • the PCR products were purified using a Whatman Polyfiltr ⁇ nics 100 ⁇ l 384 well unifilter plate essentially according to the manufacturers protocol.
  • the purified DNA was eluted in 50 ⁇ l of distilled water.
  • Sequencing reactions were set up using Applied Biosystems Big Dye Terminator chemistry essentially according to the manufacturers protocol.
  • the purified PCR products were sequenced in both directions using the primer sets described previously or those represented below by the nucleotide positions of their initial and final nucleotides, which correspond to positions in Figure 1.. Reaction products were purified by isopropanol precipitation, and run on an Applied Biosystems 3700 DNA Analyzer.
  • PS10 R 2518011 1080 T G 640 S214A a PolyId is a unique identifier assigned to each PS by Genaissance Pharmaceuticals, Inc. R Previously reported in literature
  • This example illustrates analysis of the NATl polymo ⁇ hisms identified in the Index Repository for human genotypes and haplotypes.
  • the different genotypes containing these polymo ⁇ hisms that were observed in the reference population are shown in Table 3 below, with the haplotype pair indicating the combination of haplotypes determined for the individual using the haplotype derivation protocol described below.
  • Table 3 homozygous positions are indicated by one nucleotide and heterozygous positions are indicated by two nucleotides. Missing nucleotides in any given genotype in Table 3 were inferred based on linkage disequilibrium and/or Mendelian inheritance.
  • Table 3 Genotypes and Haplotype Pairs Observed for NATl Gene Genotype , Polymorphic Sites
  • haplotype pairs shown in Table 3 were estimated from the unphased genotypes using a computer-implemented extension of Clark's algorithm (Clark, A.G.1990 Mol Bio Evol 7, 111-122) for assigning haplotypes to umelated individuals in a population sample.
  • haplotypes are assigned directly from individuals who are homozygous at all sites or heterozygous at no more than one of the variable sites.
  • This list of haplotypes is augmented with haplotypes obtained from two families (one three-generation Caucasian family and one two-generation African- American family) and then used to deconvolute the unphased genotypes in the remaining (multiply heterozygous) individuals.
  • Table 5 the number of chromosomes characterized by a given haplotype is shown, arranged by the ethnic background of the subjects in the index repository.
  • Table 6 the number of subjects characterized by a given haplotype pair is shown, arranged by the ethnic background of the subjects in the index repository.
  • AF African or African- American
  • AS Asian
  • CA Caucasian
  • HL Hispanic-Latino
  • AM Native Americans.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux polymorphismes nucléotidiques simples dans le gène humain N-acetyltransferase 1(arylamine N-acetyltransferase) (NAT1). En outre, l'invention concerne également différents génotypes, haplotypes et paires d'haplotypes du gène NAT1 existant dans la population. Cette invention porte aussi sur des compositions et des procédés pour haplotyper et/ou génotyper le gène NAT1 chez un individu, ainsi que sur des polynucléotides contenant un ou plusieurs polymorphismes NAT1.
PCT/US2001/011852 2000-04-12 2001-04-11 Haplotypes du gene nat1 Ceased WO2001079551A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001255316A AU2001255316A1 (en) 2000-04-12 2001-04-11 Haplotypes of the nat1 gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19677300P 2000-04-12 2000-04-12
US60/196,773 2000-04-12

Publications (1)

Publication Number Publication Date
WO2001079551A1 true WO2001079551A1 (fr) 2001-10-25

Family

ID=22726757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011852 Ceased WO2001079551A1 (fr) 2000-04-12 2001-04-11 Haplotypes du gene nat1

Country Status (2)

Country Link
AU (1) AU2001255316A1 (fr)
WO (1) WO2001079551A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069189A3 (fr) * 2003-02-04 2005-07-28 Innovaceuticals Inc Procede pour inventorier les enzymes metabolisant des medicaments
WO2021185275A1 (fr) * 2020-03-17 2021-09-23 博尔诚（北京）科技有限公司 Composition de sonde pour détecter 11 cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUHN ET AL.: "Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1)", BIOCHEMICAL PHARMACOLOGY, vol. 58, no. 11, 1999, pages 1759 - 1764, XP002944272 *
DOLL ET AL.: "Identification of a novel allele a the human NAT1 acetyltransferase locus", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 233, 1997, pages 584 - 591, XP002944271 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069189A3 (fr) * 2003-02-04 2005-07-28 Innovaceuticals Inc Procede pour inventorier les enzymes metabolisant des medicaments
WO2021185275A1 (fr) * 2020-03-17 2021-09-23 博尔诚（北京）科技有限公司 Composition de sonde pour détecter 11 cancers

Also Published As

Publication number Publication date
AU2001255316A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
WO2001090122A2 (fr) Haplotypes du gene ctla4
WO2001092582A1 (fr) Haplotypes du gene ube3a
WO2001079229A2 (fr) Haplotypes du gene cxcr4
WO2001079230A2 (fr) Haplotypes du gene ugt1a1
WO2002026764A2 (fr) Haplotypes du gene ccr6
WO2001085998A1 (fr) Haplotypes du gene crybb1
WO2002090512A2 (fr) Haplotypes du gene nnmt
WO2001058914A2 (fr) Haplotypes du gene de l'interleukine 15
WO2001079551A1 (fr) Haplotypes du gene nat1
WO2001079547A1 (fr) Haplotypes du gene scn2b
WO2001094376A1 (fr) Haplotypes du gene cfl1
WO2002018413A2 (fr) Haplotypes du gene scya2
WO2002053575A1 (fr) Isogenes cibles de medicaments : polymorphismes dans le gene de la lecithine-cholesterol acyltransferase
WO2001079218A2 (fr) Haplotypes du gene calm1
WO2002018647A1 (fr) Haplotypes du gene gng7
WO2001098315A2 (fr) Haplotypes du gene hmgcl
WO2002020556A2 (fr) Haplotypes du gene gpr68
WO2001087904A2 (fr) Haplotypes du gene gpr4
WO2002032930A2 (fr) Haplotypes du gene scya21
WO2002063044A2 (fr) Haplotypes du gene il15
WO2002016631A1 (fr) Haplotypes du gene ifng
WO2002090378A2 (fr) Haplotypes du gene de ces2
WO2002051857A1 (fr) Isogenes cibles de medicaments: polymorphismes dans le gene du neuropeptide y
WO2001077126A2 (fr) Haplotypes du gene hsd3b2
WO2001074833A2 (fr) Haplotypes du gene chrnb2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP